Home › Macular Degeneration › Florida › Sarasota
Macular Degeneration clinical trials in Sarasota, FL
4 studies for Macular Degeneration are looking for participants at sites in and around Sarasota (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
RecruitingPhase 3
- Retina Group of Florida, RAS-Sarasota Retina Center-Ophthalmology, Sarasota
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
RecruitingPhase 2
- Retina Group of Florida, Sarasota
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
RecruitingPhase 2/3
- Retina Group of Florida (Site 065), Sarasota
Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD
Recruiting
- Sarasota Retina Institute, Sarasota
About Macular Degeneration
Macular degeneration, or age-related macular degeneration (AMD), is the leading cause of vision loss in older adults. Learn about the types and what might help.
More about Macular Degeneration on MedlinePlus
Macular Degeneration trials in other cities
- Dallas, TX12 studies
- Erie, PA9 studies
- The Woodlands, TX9 studies
- Sacramento, CA7 studies
- Carmel, IN7 studies
- Santa Monica, CA7 studies
- Hagerstown, MD7 studies
- Houston, TX7 studies
- Phoenix, AZ7 studies
- McAllen, TX7 studies
- Cleveland, OH7 studies
- Reno, NV7 studies
Other studies in Sarasota
- Metastatic Cancer17 studies
- Non-Small Cell Lung Cancer17 studies
- Colorectal Cancer15 studies
- Ovarian Cancer14 studies
- Breast Cancer12 studies
- Endometrial Cancer12 studies
- Cancer (all types)10 studies
- Triple-Negative Breast Cancer8 studies
- Lung Cancer8 studies
- Pancreatic Cancer7 studies
- Head and Neck Squamous Cell Carcinoma7 studies
- Atrial Fibrillation6 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.